Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of "Hold" from Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY - Get Free Report) have been assigned a consensus recommendation of "Hold" from the thirteen brokerages that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $24.82.

Several research firms recently weighed in on PGNY. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Finally, Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th.

Insiders Place Their Bets

In other news, CEO Peter Anevski acquired 209,500 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now owns 441,463 shares of the company's stock, valued at $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of the company's stock in a transaction dated Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the acquisition, the chairman now owns 228,269 shares of the company's stock, valued at $3,350,988.92. This trade represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Progyny

Hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its holdings in Progyny by 56.8% in the third quarter. Victory Capital Management Inc. now owns 113,336 shares of the company's stock valued at $1,900,000 after acquiring an additional 41,035 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Progyny in the 3rd quarter worth about $77,000. King Luther Capital Management Corp boosted its stake in shares of Progyny by 39.1% during the 3rd quarter. King Luther Capital Management Corp now owns 164,760 shares of the company's stock valued at $2,761,000 after purchasing an additional 46,281 shares in the last quarter. Aurora Investment Counsel purchased a new position in shares of Progyny during the third quarter valued at about $1,280,000. Finally, Intech Investment Management LLC raised its stake in Progyny by 282.0% in the third quarter. Intech Investment Management LLC now owns 42,013 shares of the company's stock worth $704,000 after buying an additional 31,014 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Up 0.8 %

PGNY traded up $0.18 on Thursday, hitting $21.86. The company's stock had a trading volume of 5,122,408 shares, compared to its average volume of 1,616,181. The firm has a market cap of $1.87 billion, a P/E ratio of 37.69, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41. Progyny has a 12 month low of $13.39 and a 12 month high of $38.98. The company's 50 day simple moving average is $21.93 and its 200-day simple moving average is $18.59.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.